Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction
Open Access
- 15 August 2007
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 64 (4) , 439-444
Abstract
What is already known about this subject • All inhaled corticosteroids are absorbed into the systemic circulation and hence have the potential to cause adverse systemic effects.• Plasma drug concentrations following inhalation of 1000 µg fluticasone are considerably lower in people with airflow obstruction than in healthy volunteers but this is not the case for budesonide. What this study adds • This is the first study to determine whether changes in airflow obstruction within an individual affect the systemic absorption of inhaled fluticasone and budesonide;• Plasma concentrations of fluticasone and, to a lesser extent, those of budesonide were lower when the drugs were inhaled following induced bronchoconstriction;• The lower plasma concentrations of corticosteroids seen when the drugs were inhaled following induced bronchoconstriction is likely to reflect variations that will occur with fluctuations in airway caliber in asthma.Aims: To determine whether and to what extent bronchoconstriction affects plasma concentrations of fluticasone and budesonide following inhalation.Methods: Twenty people with mild asthma inhaled 1000 µg fluticasone (Accuhaler®) plus 800 µg budesonide (Turbohaler®) on two visits. On one occasion, prior to drug inhalation, FEV1 was decreased by at least 25% using inhaled methacholine. Plasma drug concentrations were measured for each drug over 5 h and area under the plasma concentration‐time curve (AUC(0,5 h)) compared between visits.Results: The mean difference in FEV1 prior to drug inhalation on the 2 days was 33%. AUC(0,5 h) values for fluticasone and budesonide were lower by a median of 60% (IQR 36–75) and 29% (IQR 2–44), respectively, when administered following bronchoconstriction; the reduction was greater for fluticasone than for budesonide, P = 0.007.Conclusions: The lower plasma concentrations of fluticasone and, to a lesser extent, budesonide seen when the drugs were inhaled following induced bronchoconstriction, is likely to reflect variations that will occur with fluctuations in airway caliber in asthma.Keywords
This publication has 17 references indexed in Scilit:
- How the Lung Handles Drugs: Pharmacokinetics and Pharmacodynamics of Inhaled CorticosteroidsProceedings of the American Thoracic Society, 2004
- A population based case-control study of cataract and inhaled corticosteroidsBritish Journal of Ophthalmology, 2003
- Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary diseaseBritish Journal of Clinical Pharmacology, 2003
- Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjectsThorax, 2003
- SPE/RIA vs LC/MS for measurement of low levels of budesonide in plasmaBiomedical Chromatography, 2002
- Inhaled Corticosteroids and Hip Fracture: A Population-based Case–Control StudyAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Survey of adrenal crisis associated with inhaled corticosteroids in the United KingdomArchives of Disease in Childhood, 2002
- Effects of Inhaled Glucocorticoids on Bone Density in Premenopausal WomenNew England Journal of Medicine, 2001
- Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover studyThe Lancet, 2000
- A sensitive LC–MS/MS method for the quantification of fluticasone propionate in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2000